Why Quality Data is the Foundation of Next-Gen Antibody Development
Discover why superior data is now the most critical driver of next-generation antibody innovation.
The global antibody therapeutics market is forecast to reach $865 billion by 2032, powered by explosive growth in clinical trials and accelerating investment in AI-driven discovery. Yet most R&D teams remain constrained by fragmented, low-quality, or inaccessible data—slowing timelines, increasing development costs, and undermining the potential of AI models designed to transform the drug discovery process.
This mini-report reveals how high-quality, large-scale datasets are reshaping the future of antibody development and enabling biotech innovators to compress years of discovery work into weeks.
Key Insights Include:
- The data crisis limiting innovation — Antibody–antigen relationships are buried in patents, scattered across literature, or compromised by poor-quality open-source datasets, leading to model bias and costly failures.
- Why scale and accuracy matter — AI/ML models require comprehensive datasets covering sequences, structures, binding affinities, developability metrics, and more to generate reliable predictions and novel therapeutic candidates.
- The Patsnap advantage — The Lao Tzu Antibody-Antigen Dataset delivers:
- 120,000+ curated antibody–antigen pairings
- 20,000+ affinity measurements and 24,000+ IC50/EC50 values
- 2,000+ manually curated epitopes
- 90%+ accuracy through expert-validated extraction
These elements create a robust foundation for AI-powered discovery and validation workflows.
- Real-world impact — Organisations using Lao Tzu achieve dramatic efficiency gains, reducing candidate identification from months to weeks, lowering failure rates, and uncovering novel, patentable sequences with greater confidence.
With industry-wide competition intensifying, quality data is no longer optional—it is the defining advantage in reaching the next frontier of antibody therapeutics.
Download the report to learn how high-fidelity data can accelerate antibody R&D and unlock the full potential of AI-driven discovery.
White Paper from 